Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate

Oncogene volume 30, pages 4026–4037 (2011)Cite this article

Subjects

Abstract

There has been growing interest among the public and scientists in dichloroacetate (DCA) as a potential anticancer drug. Credible evidence exists for the antitumor activity of this compound, but high concentrations are needed for significant therapeutic effect. Unfortunately, these high concentrations produce detrimental side effects involving the nervous system, thereby precluding its use for cancer treatment. The mechanistic basis of the compound's antitumor activity is its ability to activate the pyruvate dehydrogenase complex through inhibition of pyruvate dehydrogenase kinase. As the compound inhibits the kinase at micromolar concentrations, it is not known why therapeutically prohibitive high doses are needed for suppression of tumor growth. We hypothesized that lack of effective mechanisms for the entry of DCA into tumor cells may underlie this phenomenon. Here we show that SLC5A8 transports DCA very effectively with high affinity. This transporter is expressed in normal cells, but expression is silenced in tumor cells by epigenetic mechanisms. The lack of the transporter makes tumor cells resistant to the antitumor activity of DCA. However, if the transporter is expressed in tumor cells ectopically, the cells become sensitive to the drug at low concentrations. This is evident in breast cancer cells, colon cancer cells and prostate cancer cells. Normal cells, which constitutively express the transporter, are however not affected by the compound, indicating tumor cell-selective therapeutic activity. The mechanism of the compound's antitumor activity still remains its ability to inhibit pyruvate dehydrogenase kinase and force mitochondrial oxidation of pyruvate. As silencing of SLC5A8 in tumors involves DNA methylation and its expression can be induced by treatment with DNA methylation inhibitors, our findings suggest that combining DCA with a DNA methylation inhibitor would offer a means to reduce the doses of DCA to avoid detrimental effects associated with high doses but without compromising antitumor activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Baylin SB . (2005). DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2: S4–S11.

    Article  CAS  Google Scholar 

  • Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al. (2007). A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37–51.

    Article  CAS  Google Scholar 

  • Brahimi-Horn MC, Chiche J, Pouyssegur J . (2007). Hypoxia signaling controls metabolic demand. Curr Opin Cell Biol 19: 223–229.

    Article  CAS  Google Scholar 

  • Brandsma D, Dorlo TP, Haanen JH, Beijnen JH, Boogerd W . (2010). Severe encephalopathy and polyneuropathy induced by dichloroacetate. J Neurol 257: 2099–2100.

    Article  Google Scholar 

  • Calcutt NA, Lopez VL, Bautista AD, Mizisin LM, Torres BR, Shroads AL et al. (2009). Peripheral neuropathy in rats exposed to dichloroacetate. J Neuropathol Exp Neurol 68: 985–993.

    Article  CAS  Google Scholar 

  • Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S et al. (2008). Dichloroacetate (DCA) sensitizes both wild type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68: 1223–1231.

    Article  CAS  Google Scholar 

  • Chen Z, Lu W, Garcia-Prieto C, Huang P . (2007). The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39: 267–274.

    Article  CAS  Google Scholar 

  • Coady MJ, Chang MH, Charron FM, Plata C, Wallendorff B, Sah JF et al. (2004). The tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J Physiol 557: 719–731.

    Article  CAS  Google Scholar 

  • Cooper RH, Randle PJ, Denton RM . (1974). Regulation of heart muscle pyruvate dehydrogenase kinase. Biochem J 143: 625–641.

    Article  CAS  Google Scholar 

  • Ganapathy V, Gopal E, Miyauchi S, Prasad PD . (2005). Biological functions of SLC5A8, a candidate tumor suppressor. Biochem Soc Trans 33: 237–240.

    Article  CAS  Google Scholar 

  • Ganapathy V, Thangaraju M, Gopal E, Itagaki S, Miyauchi S, Prasad PD . (2008). Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 10: 193–199.

    Article  CAS  Google Scholar 

  • Ganapathy V, Thangaraju M, Prasad PD . (2009). Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121: 29–40.

    Article  CAS  Google Scholar 

  • Gatenby RA, Gillies RJ . (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891–899.

    Article  CAS  Google Scholar 

  • Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V . (2005). Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by Slc5a8, a member of the Na+/glucose cotransporter gene family. Biochem J 388: 309–316.

    Article  CAS  Google Scholar 

  • Gopal E, Fei YJ, Sugawara M, Miyauchi S, Zhuang L, Martin PM et al. (2004). Expression of Slc5a8 in kidney and its role in Na+-coupled transport of lactate. J Biol Chem 279: 44522–44532.

    Article  CAS  Google Scholar 

  • Gupta N, Martin PM, Prasad PD, Ganapathy V . (2006). SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 78: 2419–2425.

    Article  CAS  Google Scholar 

  • Heshe D, Hoogestraat S, Brauckmann C, Karst U, Boos J, Lanvers-Kaminsky C . (2010). Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother Pharmacol 67: 647–655.

    Article  Google Scholar 

  • Hong C, Maunakea A, Jun P, Bollen AW, Hodgson JG, Goldenberg DD et al. (2005). Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res 65: 3617–3623.

    Article  CAS  Google Scholar 

  • Jackson VN, Halestrap AP . (1996). The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2′,7′-bis (carboxyethyl)-5(6)-carboxyfluorescein. J Biol Chem 271: 861–868.

    Article  CAS  Google Scholar 

  • Kim JW, Dang CV . (2006). Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66: 8927–8930.

    Article  CAS  Google Scholar 

  • Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L et al. (2003). SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100: 8412–8417.

    Article  CAS  Google Scholar 

  • Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG . (2010). Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer 102: 1746–1752.

    Article  CAS  Google Scholar 

  • Martin PM, Gopal E, Ananth S, Zhuang L, Itagaki S, Prasad BM et al. (2006). Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem 98: 279–288.

    Article  CAS  Google Scholar 

  • Mathupala SP, KO YH, Pedersen PL . (2010). The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797: 1225–1230.

    Article  CAS  Google Scholar 

  • Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E et al. (2010). Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2: 31–34.

    Article  Google Scholar 

  • Michelakis ED, Webster L, Mackey JR . (2008). Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99: 989–994.

    Article  CAS  Google Scholar 

  • Miyauchi S, Gopal E, Babu E, Sonne SR, Kubo Y, Umapathy NS et al. (2010). Sodium-coupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter. Biochim Biophys Acta 1798: 1164–1171.

    Article  CAS  Google Scholar 

  • Miyauchi S, Gopal E, Fei YJ, Ganapathy V . (2004). Functional identification of SLC5A8, a tumor suppressor downregulated in colon cancer, as a Na+-coupled transporter for short-chain fatty acids. J Biol Chem 279: 13293–13296.

    Article  CAS  Google Scholar 

  • Park JY, Helm JF, Zheng W, Ly QP, Hodul PJ, Centeno BA et al. (2008). Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas 36: e32–e39.

    Article  CAS  Google Scholar 

  • Park JY, Zheng W, Kim D, Cheng JQ, Kumar N, Ahmad N et al. (2007). Candidate tumor suppressor gene SLC5A8 is frequently downregulated by promoter hypermethylation in prostate cancer. Cancer Detect Prev 31: 359–365.

    Article  CAS  Google Scholar 

  • Pearson H . (2007). Cancer patients opt for unapproved drug. Nature 446: 474–475.

    Article  CAS  Google Scholar 

  • Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N et al. (2005). Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations is classical papillary thyroid carcinomas. J Clin Endocrinol Metab 90: 3028–3035.

    Article  CAS  Google Scholar 

  • Semenza GL . (2010). HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51–56.

    Article  CAS  Google Scholar 

  • Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO . (1998). Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 30: 499–539.

    Article  CAS  Google Scholar 

  • Stacpoole PW, Kurtz TL, Han Z, Langaee T . (2008). Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 60: 1478–1487.

    Article  CAS  Google Scholar 

  • Stacpoole PW, Nagaraja NV, Hutson AD . (2003). Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 43: 683–691.

    Article  CAS  Google Scholar 

  • Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR et al. (2010). Sodium dichloroacetate (DCA) selectively targets cells with defects in the mitochondrial ETC. Int J Cancer 127: 2510–2519.

    Article  CAS  Google Scholar 

  • Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC . (2010). Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 120: 253–260.

    Article  CAS  Google Scholar 

  • Thangaraju M, Carswell KN, Prasad PD, Ganapathy V . (2009b). Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 417: 379–389.

    Article  CAS  Google Scholar 

  • Thangaraju M, Cresci G, Itagaki S, Mellinger J, Browning DD, Berger FG et al. (2008). Sodium-coupled transport of the short-chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J Gastrointest Surg 12: 1773–1782.

    Article  Google Scholar 

  • Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD et al. (2006). SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 66: 11560–11564.

    Article  CAS  Google Scholar 

  • Thangaraju M, Karunakaran S, Itagaki S, Gopal E, Elangovan S, Prasad PD et al. (2009a). Transport via SLC5A8 with subsequent inhibition of histone deacetylases HDAC1 and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115: 4655–4666.

    Article  CAS  Google Scholar 

  • Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A et al. (2004). Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 25: 134–140.

    Article  CAS  Google Scholar 

  • Vander Heiden MG, Cantley LC, Thompson CB . (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029–1033.

    Article  CAS  Google Scholar 

  • Warburg O . (1956). On the origin of cancer cells. Science 123: 309–314.

    Article  CAS  Google Scholar 

  • Weimer LH, Sachdev N . (2009). Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 9: 69–75.

    Article  CAS  Google Scholar 

  • Whitehouse S, Cooper RH, Randle PJ . (1974). Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 141: 761–774.

    Article  CAS  Google Scholar 

  • Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I . (2008). Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109: 394–402.

    Article  CAS  Google Scholar 

  • Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y . (2010). Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem 340: 31–40.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The work described here is supported in part by the National Institutes of Health Grant CA131402.

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA, USA

    E Babu, S Ramachandran, V CoothanKandaswamy, S Elangovan, P D Prasad, V Ganapathy & M Thangaraju

Authors
  1. E Babu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Ramachandran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V CoothanKandaswamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Elangovan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P D Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Ganapathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Thangaraju
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Thangaraju.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Babu, E., Ramachandran, S., CoothanKandaswamy, V. et al. Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. Oncogene 30, 4026–4037 (2011). https://doi.org/10.1038/onc.2011.113

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2011.113

Keywords

This article is cited by

Search

Advanced search

Quick links